Get the Stockscreener App
1.41
0.70%
-0.01
After Hours:
1.39
-0.02
-1.42%
Organogenesis Holdings Inc stock is traded at $1.41, with a volume of 603.50K.
It is down -0.70% in the last 24 hours and down -18.97% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$1.42
Open:
$1.43
24h Volume:
603.50K
Relative Volume:
0.77
Market Cap:
$181.43M
Revenue:
$514.70M
Net Income/Loss:
$2.72M
P/E Ratio:
-8.8735
EPS:
-0.1589
Net Cash Flow:
$17.08M
1W Performance:
-0.70%
1M Performance:
-18.97%
6M Performance:
-42.21%
1Y Performance:
-69.87%
1-Day Range:
$1.36
$1.4396
1-Week Range:
$1.36
$1.495
52-Week Range:
$1.34
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
1.41 | 182.72M | 514.70M | 2.72M | 17.08M | -0.1589 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.01B | 14.57B | -296.50M | 1.64B | -0.259 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Undervalued Opportunities: Penny Stocks To Watch In September 2026 - simplywall.st
ORGO stock gains on a fresh price snapshot - AD HOC NEWS
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a Potential 47% Upside in Regenerative Medicine - DirectorsTalk Interviews
Organogenesis (ORGO) Drops 7% to $1.59: Wound Care Specialist Nears Critical SupportPercent Below MA - dars.gov.et
ORGO Q2 2026 Earnings: Significant EPS Miss Highlights Profitability ChallengesDiluted EPS Report - careplusvn.com
Organogenesis stock trades without a fresh catalyst, recent results define the picture - ad-hoc-news.de
Organogenesis (ORGO) Quarter in Focus: Reported EPS Misses Expectations for the Current Session; Closing Reaction - vinanet.vn
ORGO | Organogenesis Holdings Inc. Class FinancialsRevenue Breakdown - Quiver Quantitative
Organogenesis (ORGO) Shares: Moves 2.17% Down to $1.80 in the Latest Session; Chart View - dars.gov.et
Spotlighting Anixa Biosciences And 2 Other Noteworthy Penny Stocks - Sahm
Organogenesis (ORGO) Chart: Moves 3.35% Up to $1.85 on the Day; Current Setup: the Near-Term Reference Band Stretches From $1.76 to $1.94 in Latest TradingRSI Overbought Alerts - vinanet.vn
Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Organogenesis (ORGO) Q2 2026 Earnings Call Transcript - AOL.com
Oragenics: Q2 Earnings Snapshot - AOL.com
Organogenesis, lured to RI with tax credits, is bleeding money - The Business Journals
OrganiGram: Fiscal Q3 Earnings Snapshot - AOL.com
Organogenesis Holdings, Inc. Class A Revenue Breakdown – MUN:2PQ - TradingView
Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Stock News Today - TradingKey
Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed? - Yahoo Finance
Organogenesis (NASDAQ:ORGO) Cut to Strong Sell at Wall Street Zen - MarketBeat
Organogenesis Shares Plunge After Revenue Slump, Wider Loss and Lower Outlook - Moomoo
Truist Adjusts Price Target on Organogenesis to $2 From $3, Maintains Hold Rating - marketscreener.com
Truist Financial Has Lowered Expectations for Organogenesis (NASDAQ:ORGO) Stock Price - MarketBeat
Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower By Investing.com - Investing.com Australia
Form 8K Organogenesis Holdings Inc For: 6 August By Investing.com - Investing.com Nigeria
Organogenesis Holdings enters at-the-market sales agreement for up to $75 million - Investing.com Nigeria
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Potential 24% Upside For Investors - DirectorsTalk Interviews
Organogenesis Q2 Earnings Call Highlights - Yahoo Finance
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results - The Manila Times
Organogenesis earnings missed by $0.42, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower - Investing.com
Transcript : Organogenesis Holdings Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
Organogenesis: Q2 Earnings Snapshot - Barchart.com
Organogenesis Holdings Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
ORGO: Q2 2026 revenue plunged 58% and net loss widened sharply amid ongoing market and regulatory challenges - TradingView
Organogenesis (Nasdaq: ORGO) sets up $75M at-the-market stock sale - Stock Titan
Organogenesis Holdings Inc. Q2 2026: Revenue $42.8M, EPS $(0.77) — 10-Q Summary - tradingview.com
Organogenesis (NASDAQ: ORGO) hit by 58% sales drop and $149M first-half loss - Stock Titan
Organogenesis Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Organogenesis Holdings reports Q2 2026 revenue $42.8M, net loss $96.3M - TradingView
Organogenesis Holdings Inc. Revises Revenue Guidance for the Second Half of the Year Ending December 31, 2026 - marketscreener.com
Organogenesis Holdings, Inc. Class A Revenue Breakdown – LS:A2PA31 - TradingView
ORGO Q2'26 Earnings: EPS estimate is (0.35) USD - TradingView
Organogenesis Holdings Inc. expected to post a loss of 35 cents a shareEarnings Preview - TradingView
ORGO Q1 2026 Earnings: Deep EPS Miss Signals Persistent Profitability PressuresEarnings Quality Score - vinanet.vn
Organon: Q2 Earnings Snapshot - AOL.com
Organogenesis (ORGO) to Release Quarterly Earnings on Thursday - MarketBeat
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers - The Manila Times
Organogenesis Holdings Inc (ORGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):